Comment on

• Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

  Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F. Necchi A, et al. Eur Urol. 2020 Apr;77(4):439-446. doi: 10.1016/j.eururo.2019.10.026. Epub 2019 Nov 8. Eur Urol. 2020. PMID: 31708296 Clinical Trial.
• Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.

  Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, Giannatempo P, Lucianò R, Salonia A, Madison R, Ali SM, Chung JH, Ross JS, Briganti A, Montorsi F, De Cobelli F, Messina A. Necchi A, et al. Eur Urol. 2020 May;77(5):636-643. doi: 10.1016/j.eururo.2019.12.016. Epub 2019 Dec 25. Eur Urol. 2020. PMID: 31882281
• Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme.

  van Hensbergen M, van Osch FHM, Jochems S, James ND, Wallace DMA, Wesselius A, Cheng KK, Bryan RT, Zeegers MP. van Hensbergen M, et al. Eur J Cancer Prev. 2020 Mar;29(2):110-118. doi: 10.1097/CEJ.0000000000000525. Eur J Cancer Prev. 2020. PMID: 32012137
• Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer.

  Krajewski W, Rodríguez Faba O, Breda A, Pisano F, Poletajew S, Tukiendorf A, Zdrojowy R, Kołodziej A, Palou J. Krajewski W, et al. World J Urol. 2020 Dec;38(12):3177-3182. doi: 10.1007/s00345-020-03130-1. Epub 2020 Feb 18. World J Urol. 2020. PMID: 32072228